Clinical Trials to Real World:

Slides:



Advertisements
Similar presentations
The Diabetic Retinopathy Clinical Research Network
Advertisements

The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.
TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia Dr.Muhammad Hamza North Devon District NHS Hospital NICE.
Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: VEGFA and VEGFR1 and Response to Anti-VEGF Hagstrom SA, Ying G, Pauer GJT, et.
Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,
Pyoderma Gangrenosum  Severe, autoinflammatory, ulcerative disease of the skin  Classically presents with rapidly forming, painful ulcers of variable.
The Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year.
Secondary Analysis of Clinical Trials Data – A Biostatistician’s Experience Gui-shuang Ying, PhD Center for Preventive Ophthalmology and Biostatistics.
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
The Diabetic Retinopathy Clinical Research Network
A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice Ophthalmologica 2011;225:112–119.
Upfront Combination Therapy vs Step-Up Approach for PAH:
The Diabetic Retinopathy Clinical Research Network
Copyright © 2013 American Medical Association. All rights reserved.
Retina Centre of Ottawa Clinical Trials
Copyright © 2003 American Medical Association. All rights reserved.
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
nAMD: Choosing the Best Treatment for your Patient
Major Depressive Disorder: Latest Clinical Update
Clinical Trials in IBD.
How the Latest Data in MDD Can Guide Treatment Decisions:
Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.
Why Gene Therapy for Hemophilia?
Updates on Emerging GLP-1 Receptor Agonists
Introducing JAK Inhibitors in Rheumatoid Arthritis
Expert Perspectives on Clinically Challenging Cases in Narcolepsy
Does One Size Fit All in Obesity Management?
Progression After Cancer Immunotherapy in Advanced NSCLC
The HCV Revolution: Are You and Your Practice Ready?
Epidemiology Venous Pathophysiology Etiology.
Optimizing Outcomes in the Management of GIST
nAMD: Switching Therapies - what you need to know
New Data in nAMD: What Does the Future Hold?
Do CNV Subtypes Matter for Prognosis, Diagnosis, and Treatment?
Are We Closer to Personalized Medicine in MS?
nAMD: New Drugs and Practice Patterns to Improve Patient Outcomes
Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response.
EHL Technologies in Hemophilia Care
A Primer on Medication Delivery Systems in COPD Management
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Improving Outcomes in Psoriatic Arthritis
NOACs in AF: Consequences of Underdosing and NonAdherence
Key Questions for nAMD Treatment Success
A Primer on Medication Delivery Systems in COPD Management
Wet AMD trials Hibba Soomro.
Short-Term Evaluation of Combination
Treatment-Resistant Schizophrenia
nAMD: Choosing the Best Treatment for your Patient
Management of Systemic Lupus Erythematosus
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Insulin in Diabetes Management: Effective Patient Selection Is Key
Critical Decision Points in Insomnia
The Role of Lucentis in the treatment of Visual impairment due to Diabetic Macula Oedema Dr Dan Bwonya Mengo Hospital,
Should We Dry the Retina Faster for Longer
NOACs in AF: Consequences of Underdosing and NonAdherence
New Perspectives for Your nAMD Patients
Applying the Latest Data on Treat-and-Extend Strategies to Clinical Cases in nAMD.
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:
AMD Therapy: Where Are We Now and Where Are We Going?
Real-World Evidence.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
The Building Blocks of Homocystinuria and Homocysteinemia Management
Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.
What's New in PAH?.
The Future Is Now: Gene Therapy for Inherited Retinal Diseases
nAMD: Why Anatomical Outcomes Matter
Characterizing Virological Suppression in Today's Treatment Paradigm
Psoriatic Arthritis.
Presentation transcript:

Clinical Trials to Real World:

Topics of Discussion

Two Key Questions

MARINA Trial: Mean Change in VA

ANCHOR Trial: Mean Change in VA

VIEW 1/2 Trial Results: Mean Change in BCVA From Baseline to Week 52

Monthly Injections: The Gold Standard of Treatment

LUMINOUS Study: Recruitment From Third Interim Analysis

LUMINOUS: VA Gains in Treatment-Naive Patients Stratified by Injection Frequency Over 1 Year

LUMINOUS: VA Stratified by Injection Frequency and Loading Dose

LUMINOUS: Safety Outcomes in Treatment-Naive Patients Over 1 Year

AURA Study: Summary of Mean Injections and VA Scores

AURA Study: Mean Change in VA Score From Baseline Over Time for All Patients by Country

LUMIERE Study: Changes in VA

UNCOVER Study: Medical Coverage Categories

UNCOVER: Frequency of Ranibizumab Injections/Year Were Lowest in Self-Paid Category

Real-World Considerations Contributing to Low Injection Frequency

Treat-and-Extend Regimen in Real-World Clinical Practice

Fight Retinal Blindness Study: 12-Month Outcomes

CATT 5-Year Study Results: Percent of Eyes With Fluid for 552 Eyes

FLUID Study: Design

FLUID Study: Summary

Importance of Qualitative Assessment on Monitoring

Concluding Remarks

Abbreviations